A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States.

Trial Profile

A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 09 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 20 Oct 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 20 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top